Mitigating risk in mRNA manufacturing when transitioning from preclinical to clinical

Learning objectives:

Identifying common challenges with preclinical and clinical transitions in mRNA manufacturing
Mitigating risk and streamlining mRNA manufacturing across phases through scale-up, process robustness, and reproducibility
Case study | Leveraging insights from a process development and engineering run

The emergence of mRNA as a versatile platform for therapeutic and vaccine development holds immense promise in reshaping the landscape of molecular medicine. Join Evan Myers, the head of the process development team for TriLink GMP services, as he addresses the pivotal transition from preclinical to clinical stages in mRNA manufacturing, highlighting key challenges and solutions to mitigate risks.

Evan will share results from extensive data points from a process and development and engineering case study, offering practical approaches to streamline mRNA production. This event is essential for professionals involved in mRNA-based vaccine and therapeutic development, delivering critical insights and solutions for transitioning manufacturing from preclinical to clinical phases.

The webinar will conclude with an interactive Q&A session, addressing your questions on essential aspects of mRNA manufacturing and strategic partnerships.

First name

Last name

Country

State/Province

Company

Job Title

Job function

Organization type

I would like to receive additional technical and educational content from the sponsor.

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Evan Myers

Associate Director, Process Development, TriLink BioTechnologies

Evan Myers is the Associate Director of Process Development at TriLink BioTechnologies, where he oversees development of capabilities for TriLink’s CDMO services platform. Evan has extensive experience in this area, having held various positions in mRNA and oligonucleotide manufacturing, GMP, and process development, where he supported several drug substances. His expertise spans biologics through synthesis, chromatography, scale-up, and process optimization covering development, manufacturing, and analytical testing.

moderator

Sy Mukherjee

Freelance healthcare journalist

Sy Mukherjee is a veteran healthcare journalist who has been covering the space with a focus on biopharma, drug development, digital health, and the intersection of medicine and technology across the health industry for more than a decade. He has served roles as: the first editor of the industry trade publication BioPharma Dive; a biopharma/digital health/healthcare-specialized reporter at Fortune Magazine for nearly six years, where he authored a biopharma/digital health newsletter, wrote articles for Fortune.com, and reported for the print magazine issue (including two cover stories focused on the digital health revolution and the intersection of data, biology, and health systems), and helped plan, cover, and moderate events at the annual Brainstorm Health conference. Additionally, he served as a consultant at the boutique path-to-market strategy life sciences consultancy IDEA Pharma, focusing on stakeholder-oriented strategic communications for biotech and pharma clients.

Sy has extensive experience moderating webinars and panels at both small and high-profile venues, including panels at Fortune Brainstorm Health and the Biden Cancer Summit. He is currently an independent and freelance journalist still focused on the same space that he's covered for his entire career.